Proteolytic control of growth factor availability

APMIS

Volumn 107, Issue 1, 1999, Pages 80-85

  Rifkin, Daniel B ^a   Mazzieri, Roberta ^a   Munger, John S ^a   Noguera, Irene ^a   Sung, Joanne ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Plasminogen activator (PA); Proteases; Transforming growth factor beta (TGF )

Indexed keywords

PLASMINOGEN ACTIVATOR; PROTEINASE; TRANSFORMING GROWTH FACTOR BETA;

CANCER GROWTH; CELL PROLIFERATION; ENZYME ACTIVATION; GROWTH REGULATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECEPTOR AFFINITY; REVIEW;

EID: 0032998208     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1699-0463.1999.tb01529.x     Document Type: Review

References (51)

1. 1. Flaumenhaft R, Rifkin DB. The regulation of growth factor action. Mol Biol Cell 1992;3:1057-65.
2. 2. Rifkin DB. Cross-talk among proteases and matrix in the control of growth factor Action. Fibrinolysis & Proteolysis 1997;11:3-9.
3. 3. Birchmeier W, Daikuhara Y, Tsubouchi H, Blasi F, Comoglio PM. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor. EMBO J 1192;11:4825-33.
4. 4. Morimoto Y, Kitamura N. Activation of hepatocyte growth factor by two homologous proteases, blood coagulation factor XIIa and hepatocyte growth factor activator. Eur J Biochem 1995;299:257-61.
5. 5. Matsumoto T, Gargosky SE, Iwasaki K, Rosenfeld RG. Identification and characterization of insulin-like growth factors (IGFs), IGF-binding proteins (IGFBP proteases in human synovial fluid. J Clin Endocrin Metabol 1996;81:150-5.
6. 6. Campbell PG, Andress DL. Plasmin degradation of insulin-like growth factor-binding protein-5 (IGFBP-5): regulation of IGFBP-5 (201-218). Am J Physiol 1197; 273: E996-E1004.
7. 7. Labou C, Silvi C, Segovia B, Benoux M. Interactions des insulin-like growth factors (IGF) et de leurs proteines de liaison avec le systeme activateur du plasminogene/ plasmine les cellules osteoblastiques en culture. Annal d'Endocrinologie 1994;55:103-7.
8. 8. Rifkin, DB. Cross-talk among proteases and matrix in the control of growth factor action. Fibrinolysis and Proteolysis 1997;11:3-9.
9. 9. Nunes I, Munger JE, Harpel JG, Nagano Y, Shapiro RL, Gleizes P-E, Rifkin DB. Structure and activation of the large latent transforming growth factor-β complex. Int J Obesity 1996; 20 (Suppl 3): S4-8.
10. 10. Flaumenhaft R, Moscatelli D, Saksela O, Rifkin DB. Role of extracellular matrix in the action of basic fibroblast growth factor: Matrix as a source of growth factor for long-term stimulation of plasminogen activator and DNA synthesis. J Cell Physiol 1989;140:75-81.
11. 11. La Rochelle WJ, May-Siroff M, Robbins KC, Aaronson SA. Novel mechanism regulating growth factor association with the cell surface: Identification of a PDGF retention domain. Genes and Dev 1991;5:1191-9.
12. 12. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993;4:1317-26.
13. 13. Gray A, Dull TJ, Ulrich A. Nucleotide sequence of epidermal growth factor cDNA predicts a 120 000 molecular weight protein precursor. Nature 1983;303:722-5.
14. 14. Mroczkowski B, Reich M, Chen K, Bell GI, Cohen S. Recombinant human epidermal growth factor precursor is a glycosylated membrane protein with biological activity. Mol Cell Biol 1989;9:2771-8.
15. 15. Rauch C, March CJ, Boswell HS, Gimpel SD, Cosman D, Williams DE. Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane and soluble forms. Cell 1990;63:235-43.
16. 16. Derynck R, Roberts AB, Winkler ME, Chen EY, Goeddel DV. Human transforming growth factor-α; precursor structure and expression in E. coli. Cell 1984;38:287-97.
17. 17. Lee DC, Rose TM, Webb NR, Tosaro GJ. Cloning and sequence analysis of a cDNA for rat transforming growth factor-α. Nature 1985;313:489-91.
18. 18. Saksela O, Rifkin DB. Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J Cell Biol 1990;110:767-76.
19. 20. Roberts AB, Sporn MB. The transforming growth factor-βs. New York: Springer-Verlag, New York, Inc, 1990.
20. 21. Massague J. The transforming growth factor-β family. Annu Rev Cell Biol 1990:6:597-641.
21. 22. Kanzaki, T, Olofsson A, Moren A, Wernstedt C, Hellman U, Miyazono K, Cluesson-Welsh L, Heldin C-H. TGF-β1 binding protein: a component of the large latent complex of TGF-β1 with multiple repeat sequences. Cell 1990;61:1051-61.
22. 23. Brown P, Wakefield L, Levinson A, Sporn M. Physiochemical activation of recombinant latent transforming growth factor-betas 1,2,3. Growth Factors 1990;3:35-43.
23. 24. Barcellos-Hoff MH, Derynck R, Tsang M L-S, Weatherbee JA. Transforming growth factor-β activation in irradiated murine mammary glands. J Clin Invest 1994;93:892-9.
24. 25. Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ulrich JE. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. J Biol Chem 1995;269:26775-82.
25. 26. Lyons RM, Keski-Oja J, Moses HL. Proteolytic activation of latent transforming growth factor-β from fibroblast conditioned medium. J Cell Biol 1988;106:1659-65.
26. 27. Sato Y, Rifkin DB. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming-β1 like molecule by plasmin during co-culture. J Cell Biol 1989;109:309-15.
27. 28. Antonelli-Olridge A, Saunders KB, Smith SR, D'Amore PA. An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci USA 1989;86:4544-8.
28. 29. Nunes I, Shapiro R, Rifkin DB. Characterization of latent TGF-β activation by murine peritoneal macrophages. J Immunol 1995;155;1450-9.
29. 30. Sato Y, Tsuboi R, Lyons RM, Moses H, Rifkin DB. Characterization of the activation of latent TGF-β by cocultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating system. J Cell Biol 1990;111:757-83.
30. 31. Odekon L, Blasi F, Rifkin DB. A requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-β to TGF-β. J Cell Physiol 1994;158:398-407.
31. 32. Kojima S, Nara K, Rifkin DB. A requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells. J Cell Biol 1993;121:3:439-48.
32. 33. Flaumenhaft R, Abe M, Sato Y, Miyazono K, Harpel JG, Heldin C-H, Rifkin DB. Role of the latent TGF-β binding protein in the activation of latent TGF-β by cocultures of endothelial cells and smooth muscle cells. J Cell Biol 1993;120:995-1002.
33. 34. Dennis PA, Rifkin DB. Cellular activation of latent transforming growth factor β requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc Natl Acad Sci USA 1991;88:580-4.
34. 35. Taipale J, Miyazono K, Heldin C-H, Keski-Oja J. Latent transforming growth factor-β1 associates to fibroblast extracellular matrix via latent TGF-β binding protein. J Cell Biol 1994;124:171-81.
35. 36. Nunes I, Gleizes P-E, Metz CN, Rifkin DB. Latent TGF-β binding protein domain involved in activation and transgluataminase-dependent cross-linking of latent TGF-β. J Cell Biol 1997;136:1151-63.
36. 37. Purchio AF, Cooper JA, Brunner AM, Lioubin MN, Gentry LE, Kovacina KS, Roth RA, Marquardt H. Identification of mannose-6-phosphate in two asparagine-linked sugar chains of recombinant transforming growth factor β1 precursor. J Biol Chem 1988;264: 14211-5.
37. 38. Miyazono K, Hellman U, Wernstelt C, Heldin C-H. Latent high molecular weight complex of transforming growth factor-β1 binding protein in the assembly and secretion of TGF-β1. EMBO J 1991;10:1091-101.
38. 39. Nykjaer A, Christensen EI, Vorum H, Hager H, Petersen CM, Roigaard H, et al. Mannose6-phosphate/ insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction. J Cell Biol 1998;141:815-28.
39. 40. Kojima S, Rifkin DB. Mechanism of retinoid-induced activation of latent transforming growth factor-β in bovine endothelial cells. J Cell Physiol 1993;155:323-32.
40. 41. Ellingsworth LW, Faltynek CR, Ruscetti FW. Induction of transforming growth factor-β1 (TGF-β1) receptor expression and TGF-β1 protein production in retinoic acid-treated HL-60: possible TGF-β1-mediated autocrine inhibition. Blood 1991;77:1248-55.
41. 42. Nunes I, Kojima S, Rifkin DB. Effects of endogenously activated transforming growth factor-β on growth and differentiation of retinoic acid treated HL-60 cells. Cancer Res 1996;56:495-9.
42. 43. Lyons RM, Keski-Oja J, Moses HL. Proteolytic activation of latent transforming growth factor-β from fibroblast conditioned medium. J Cell Biol 1998;106: 1659-65.
43. 44. Kojima S, Harpel PC, Rifkin DB. Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol 1991;113:1439-45.
44. 45. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalf JC. Activation of transforming growth factor-β is linked in transgenic apolipoprotein (a) mice. Nature 1994;370:460-2.
45. 46. Williams NR, Grace AA, Schofield PM, Chauhan A. The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nature Med 1995;1:74-9.
46. 47. Carmeliet P, Colen D. Gene manipulation and transfer of the plasminogen and coagulation system in mice. Demin Thromb Hemost 1996;22:525-42.
47. 48. Ploplis VA, Carmeliet P, Vazirzadeh S, Van Vlaenderen I, Moons L, Plow EF, Collen, D. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 1995;92:2585-93.
48. 49. Horimoto M, Kato J, Takimoto R, Terui T, Mogi Y, Niitsu Y. Identification of a transforming growth factor beta-1 activator derived from a human gastric cancer cell line. Br J Cancer 1995;72:676-82.
49. 50. Mizoi T, Ohtani H, Miyazono K, Miyazawa M, Matsuno S, Nagura H. Immunoelectron microscope localization of transforming growth factor beta 1 and latent transforming growth factor beta 1 binding protein in human gastrointestinal carcinomas: qualitative difference between cancer cells and stromal cells. Can Res 1993;53:183-90.
50. 51. Yamada T, De Souza AT, Finkelstein S, Jirtle RL. Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc Natl Acad Sci 1997;94:10351-5.
51. 52. De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 1995;11:447-9.